최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기대한한방내과학회지 = The journal of internal Korean medicine, v.40 no.6, 2019년, pp.1294 - 1302
정창운 (청연중앙연구소) , 전선우 (청연중앙연구소) , 정신영 (청연한방병원) , 조희근 (청연중앙연구소)
Objective: Glucagon-like peptide 1 (GLP-1), one of the gut peptide hormones, has an action to induce satiety, and its effect as an anti-obesity agent is known. Recently, it has been reported that many herbal medicines have an anti-diabetic effect through inhibition of DPP-4 enzyme and inducing of GL...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
비만 치료에는 무엇이 있는가? | 비만은 인체의 에너지 유입과 소비에 있어 에너지 대사가 축적에 치우친 불균형이 나타나 일어나는 체중의 증가로 정의될 수 있는 질환으로, 풍부한 영양 섭취 및 활동의 감소와 같은 현대인의 생활습관과 깊은 관련이 있는 질환 중 하나이다1,2. 비만 치료에 있어서 고강도의 생활습관 중재는 약물치료와 유사한 효과를 갖고 있는 것으로 알려져 있으나, 임상적으로 통상 약물치료를 포함한 의학적 중재와 이들 생활습관 중재를 병행하는 것이 일반적이다1 . 실제 침구치료, 한약치료 등 다양한 한의학적 중재는 단순한 생활습관 관리에 비해 유의미한 체중감소 효과를 가지고 있음이 보고되었다3 . | |
비만 치료가 한의학적 치료에서 나타나는 효과는? | 비만 치료에 있어서 고강도의 생활습관 중재는 약물치료와 유사한 효과를 갖고 있는 것으로 알려져 있으나, 임상적으로 통상 약물치료를 포함한 의학적 중재와 이들 생활습관 중재를 병행하는 것이 일반적이다1 . 실제 침구치료, 한약치료 등 다양한 한의학적 중재는 단순한 생활습관 관리에 비해 유의미한 체중감소 효과를 가지고 있음이 보고되었다3 . | |
비만의 정의는? | 비만은 인체의 에너지 유입과 소비에 있어 에너지 대사가 축적에 치우친 불균형이 나타나 일어나는 체중의 증가로 정의될 수 있는 질환으로, 풍부한 영양 섭취 및 활동의 감소와 같은 현대인의 생활습관과 깊은 관련이 있는 질환 중 하나이다1,2. 비만 치료에 있어서 고강도의 생활습관 중재는 약물치료와 유사한 효과를 갖고 있는 것으로 알려져 있으나, 임상적으로 통상 약물치료를 포함한 의학적 중재와 이들 생활습관 중재를 병행하는 것이 일반적이다1 . |
Heymsfield SB, Wadden TA. Mechanisms, Pathophysiology, and Management of Obesity. N EnglJ Med 2017;376(15):1492.
Gonzalez-Muniesa P, Martinez-Gonzalez MA, Hu FB, Despres JP, Matsuzawa Y, Loos RJF, et al. Obesity. Nat Rev Dis Primers 2017;3:17034.
EBM-based Obesity KMCPG Development Committee (Korea Institute of Oriental Medicine, The Society of Korean Medicine for Obesity Research). KMCPG-Obesity. Daejeon Korea; Elsevier Korea: 2016.
Song MY, Kim HJ, Lee MJ. The Safety Guidelines for use of Ma-huang in Obesity Treatment. Journal of Korean Oriental Association for Study of Obesity 2006;6(2):17-27.
Jo GW, Ok JM, Kim SY, Lim YW. Review on the Efficacy and Safety of Mahuang and Epedrine in the Treatment of Obesity - Focused on RCT. J Korean Med 2018;38(3):170-84.
Zell-Kanter M, Quigley MA, Leikin JB. Reduction in ephedra poisonings after FDA ban. N Engl J Med 2015;372(22):2172-4.
Hallas J, Bjerrum L, Stovring H, Andersen M. Use of a prescribed ephedrine/caffeine combination and the risk of serious cardiovascular events: a registry-based case-crossover study. Am J Epidemiol 2008;168(8):966-73.
Liu Y, Sun M, Yao H, Liu Y, Gao R. Herbal Medicine for the Treatment of Obesity: An Overview of Scientific Evidence from 2007 to 2017. Evid Based Complement Alternat Med 2017;2017:8943059.
Fu C, Jiang Y, Guo J, Su Z. Natural Products with Anti-obesity Effects and Different Mechanisms of Action. J Agric Food Chem 2016;64(51):9571-85.
Martel J, Ojcius DM, Chang CJ, Lin CS, Lu CC, Ko YF, et al. Anti-obesogenic and antidiabetic effects of plants and mushrooms. Nat Rev Endocrinol 2017;13(3):149-60.
Daneschvar HL, Aronson MD, Smetana GW. FDA-Approved Anti-Obesity Drugs in the United States. Am J Med 2016;129(8):879.
Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med 2015;373(1):11-22.
Nuffer WA, Trujillo JM. Liraglutide: A New Option for the Treatment of Obesity. Pharmacotherapy 2015;35(10):926-34.
Zhen Z, Chang B, Li M, Lian FM, Chen L, Dong L, et al. Anti-diabetic effects of a Coptis chinensis containing new traditional Chinese medicine formula in type 2 diabetic rats. Am J Chin Med 2011;39(1):53-63.
Lian F, Li G, Chen X, Wang X, Piao C, Wang J, et al. Chinese herbal medicine Tianqi reduces progression from impaired glucose tolerance to diabetes: a double-blind, randomized, placebocontrolled, multicenter trial. J Clin Endocrinol Metab 2014;99(2):648-55.
Tong XL, Wu ST, Lian FM, Zhao M, Zhou SP, Chen XY, et al. The safety and effectiveness of TM81, a Chinese herbal medicine, in the treatment of type 2 diabetes: a randomized double-blind placebo-controlled trial. Diabetes Obes Metab 2013;15(5):448-54.
Yu Y, Hao G, Zhang Q, Hua W, Wang M, Zhou W, et al. Berberine induces GLP-1 secretion through activation of bitter taste receptor pathways. Biochem Pharmacol 2015;97(2):173-7.
Al-masri IM, Mohammad MK, Tahaa MO. Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine. J Enzyme Inhib Med Chem 2009;24(5):1061-6.
Gao Y, Zhang Z, Zhu J, Li B, Li Z, Zhu W, et al. Recent progress in natural products as DPP-4 inhibitors. Future Med Chem 2015;7(8):1079-89.
Sui Y, Zhao HL, Wong VC, Brown N, Li XL, Kwan AK, et al. A systematic review on use of Chinese medicine and acupuncture for treatment of obesity. Obes Rev 2012;13(5):409-30.
Hasani-Ranjbar S, Jouyandeh Z, Abdollahi M. A systematic review of anti-obesity medicinal plants - an update. J Diabetes Metab Disord 2013;12(1):28.
Xu L, Zhao W, Wang D, Ma X. Chinese Medicine in the Battle Against Obesity and Metabolic Diseases. Front Physiol 2018;9:850.
Al-masri IM, Mohammad MK, Tahaa MO, Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine. J Enzyme Inhib Med Chem 2009;24(5):1061-6.
Yu Y, Liu L, Wang X, Liu X, Liu X, Xie L, et al. Modulation of glucagon-like peptide-1 release by berberine: in vivo and in vitro studies. Biochem Pharmacol 2010;79(7):1000-6.
Zhang Y, Ding Y, Zhong X, Guo Q, Wang H, Gao J, et al. Geniposide acutely stimulates insulin secretion in pancreatic $\beta$ -cells by regulating GLP-1 receptor/cAMP signaling and ion channels. Mol Cell Endocrinol 2016 Jul 15;430:89-96.
Brunton S. GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other? Int J Clin Pract 2014;68(5):557-67.
Xu L, Li Y, Dai Y, Peng J. Natural products for the treatment of type 2 diabetes mellitus: Pharmacology and mechanisms. Pharmacol Res 2018;130:451-65.
Pang B, Yu XT, Zhou Q, Zhao TY, Wang H, Gu CJ, et al. Effect of Rhizoma coptidis (Huang Lian) on Treating Diabetes Mellitus. Evid Based Complement Alternat Med 2015;2015:921416.
Milaneschi Y, Simmons WK, van Rossum EFC, Penninx BW. Depression and obesity: evidence of shared biological mechanisms. Mol Psychiatry 2019;24(1):18-33.
Ren L, Chen G. Rapid antidepressant effects of Yueju: A new look at the function and mechanism of an old herbal medicine. J Ethnopharmacol 2017;203:226-32.
Liu J, Yin F, Zheng X, Jing J, Hu Y. Geniposide, a novel agonist for GLP-1 receptor, prevents PC12 cells from oxidative damage via MAP kinase pathway. Neurochem Int 2007;51(6-7):361-9.
Zhang CY, Parton LE, Ye CP, Krauss S, Shen R, Lin CT, et al. Genipin inhibits UCP2-mediated proton leak and acutely reverses obesity- and high glucose-induced beta cell dysfunction in isolated pancreatic islets. Cell Metab 2006;3(6):417-27.
Guan L, Gong D, Yang S, Shen N, Zhang S, Li Y, et al. Genipin ameliorates diet-induced obesity via promoting lipid mobilization and browning of white adipose tissue in rats. Phytother Res 2018;32(4):723-32.
Shan M, Yu S, Yan H, Guo S, Xiao W, Wang Z, et al. A Review on the Phytochemistry, Pharmacology, Pharmacokinetics and Toxicology of Geniposide, a Natural Product. Molecules 2017;22(10):1689.
Berman AY, Motechin RA, Wiesenfeld MY, Holz MK. The therapeutic potential of resveratrol: a review of clinical trials. NPJ Precis Oncol 2017;1:35.
Kim J, Yang G, Kim Y, Kim J, Ha J. AMPK activators: mechanisms of action and physiological activities. Exp Mol Med 2016;48:224.
Wang L, Ma R, Liu C, Liu H, Zhu R, Guo S, et al. Salvia miltiorrhiza: A Potential Red Light to the Development of Cardiovascular Diseases. Curr Pharm Des 2017;23(7):1077-97.
Camacho S, Michlig S, de Senarclens-Bezencon C, Meylan J, Meystre J, Pezzoli M, et al. Anti-obesity and anti-hyperglycemic effects of cinnamaldehyde via altered ghrelin secretion and functional impact on food intake and gastric emptying. Sci Rep 2015;5:7919.
Zuo J, Zhao D, Yu N, Fang X, Mu Q, Ma Y, et al. Cinnamaldehyde Ameliorates Diet-Induced Obesity in Mice by Inducing Browning of White Adipose Tissue. Cell Physiol Biochem 2017;42(4):1514-25.
Alam MA, Subhan N, Rahman MM, Uddin SJ, Reza HM, Sarker SD. Effect of citrus flavonoids, naringin and naringenin, on metabolic syndrome and their mechanisms of action. Adv Nutr 2014;5(4):404-17.
Ye XP, Song CQ, Yuan P, Mao RG. $\alpha$ -Glucosidase and $\alpha$ -Amylase Inhibitory Activity of Common Constituents from Traditional Chinese Medicine Used for Diabetes Mellitus. Chinese Journal of Natural Medicines 2010;8(5):349-52.
Seyedan A, Alshawsh MA, Alshagga MA, Koosha S, Mohamed Z. Medicinal Plants and Their Inhibitory Activities against Pancreatic Lipase: A Review. Evid Based Complement Alternat Med 2015;2015:973143.
Hu J, Shi K, Meng Q. Mapping the knowledge of international Chinese medicines treatment on type 2 diabetes: A biblimetrical study. Journal of Traditional Chinese Medical Sciences 2016;3(4):263-72.
Thaiss CA, Itav S, Rothschild D, Meijer MT, Levy M, Moresi C, et al. Persistent microbiome alterations modulate the rate of post-dieting weight regain. Nature 2016 Dec 22;540(7634):544-51.
van Baak MA, Mariman ECM. Mechanisms of weight regain after weight loss - the role of adipose tissue. Nat Rev Endocrinol 2019 May;15(5):274-87.
Tong X, Xu J, Lian F, Yu X, Zhao Y, Xu L, et al. Structural Alteration of Gut Microbiota during the Ameliorationof Human Type 2 Diabetes with Hyperlipidemia by Metformin and a Traditional Chinese Herbal Formula: a Multicenter, Randomized, Open Label Clinical Trial. MBio 2018;9(3):e02392-17.
Wei X, Tao J, Xiao S, Jiang S, Shang E1, Zhu Z, et al. Xiexin Tang improves the symptom of type 2 diabetic rats by modulation of the gutmicrobiota. Sci Rep 2018;8(1):3685.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.